Sure, this is and was a known known. The glass half full version is that the cash burn for Stelis should end in a few quarters once the facilities ramp up and start delivering the existing order. And where it goes from there depends on how efficient and error / contamination free they can be in their manufacturing process. The demand for Bio-CDMO services is large enough for competition to not be a major constraint, at least in the near term.
Stelis will raise the cash that it needs from promotor warrants and other investors, so there won’t be any more burden on Strides.
| Subscribe To Our Free Newsletter |
